Supplemental Experimental Procedures
Whole Genome Sequencing The yield and integrity of native genomic DNA was verified by a PicoGreen assay to determine mass (Invitrogen, Carlsbad, CA) . Small insert dual indexed Illumina paired end libraries were constructed with the KAPA LTP sample prep kits according to the manufacturer's recommendations (KAPA Biosystems, Woburn, MA) with a few exceptions: (1) 100--500 ng of gDNA was fragmented using a Covaris E220 DNA Sonicator (Covaris, Woburn, MA) within a size range between 200--600 bp using the following settings: volume = 50 µL, temperature = 4 °C, duty cycle = 5, intensity = 4, cycle burst = 200, time = 90 seconds. (2) To prevent excessive over--amplification during PCR, cycle optimization was performed. 2 µL of the library was cycled as follows: 98 °C for 30 seconds, cycle -98 °C for 10 seconds, 65 °C for 30 seconds, and 72°C for 30 seconds. After cycles 6, 8, 10, and 12 the program was halted and a 5 µL aliquot was collected. Each cycle amplification product was evaluated on a 2.2% agarose Flash Gel (Lonza Group, Basel, Switzerland) and the optimum cycle number determined. (3) Eight PCR reactions were amplified at the determined cycle number to enrich for proper adaptor ligated fragments. Libraries were fractionated on the LabChip XT using the DNA 750 chip (Perkin Elmer, Hopkinton, MA) collecting three unique fractions: 375 bp, 475 bp, and 675 bp with a +/--5% covariance. Each fraction/library was assessed for concentration and size to determine molarity using the Qubit Fluorometer Quant--iT dsDNA HS assay (Life Technologies, Carlsbad, CA) and the Agilent BioAnalyzer High Sensitivity DNA Assay (Agilent Technologies, Santa Clara, CA), respectively. The concentration of each library fraction was verified through qPCR according to the manufacturer's protocol (Kapa Biosystems, Woburn, MA) to produce cluster counts appropriate for the Illumina HiSeq2000 platform. Each genome was loaded on HiSeq2000 version 3 flow cell according to the manufacturer's recommendations (Illumina, San Diego, CA). 2 X 101 bp read pairs were generated for each sample, yielding an average of 37.1x sequence coverage for the tumor genomes and 27.2x sequence coverage for the normal genomes ( Table S8 ). The reference--aligned whole genome sequence data and sample details for 52 tumor and non--tumor mouse tissues have been submitted to NCBI SRA study SRP061941, BioProject PRJNA248457.
Reference alignment and somatic variant detection
Specifically, 'Reference Alignment' and 'Somatic Variation' analysis pipelines were used to identify somatic single nucleotide variants (SNVs), small insertions and deletions (indels), and copy number alterations (CNVs). Alignment was performed by BWA (v0. 
Validation and Extension Sequencing of Prlr by Sanger and MiSeq
Based on the region in which truncating Prlr mutations were observed in the discovery set (chr15:10258139--10258195; mm9) two sets of primers were designed to encompass this region with approximately 50 or 100 bp additional flanking sequence on each side, respectively. Primers were designed using an in--house primer design graphical user interface (GUI) that does the following: (1) performs repeat and SNP masking; (2) reduces the amplicon size based on increasing GC--content; (3) blasts primers to verify a single unique genomic product (see Table  S10 for primer details). Primers were tailed (p1k / m13 reverse) for 3730 sequencing and ordered from Integrated DNA Technologies (IDT, Coralville, IA). Once received, primers were resuspended in 1X TE buffer. PCR reactions consisted of 5 ng DNA input, 6.25 µL of pooled and tailed primer pairs at 1.2 µM, and 6.25 µL of Kapa HiFi HotStart ReadyMix 2X (Kapa Biosystems, Wilmington, MA) at 2.5 mM. Amplification was performed in a Bio--Rad thermocycler (Bio--Rad Laboratories, Inc., Hercules, CA) with an initial denaturation (3 minutes at 95 °C) followed by 30 cycles of denaturation (20 seconds at 98 °C), primer annealing (15 seconds at 65 °C), extension (60 seconds at 72 °C) and then a final extension (60 seconds, 72 °C). After amplification, we removed reaction by--products using a 1.5:1.0 Ampure bead--to--sample ratio. A Lonza flash gel was run to confirm product. Two sequencing reactions were completed using a 2 µL DNA input, BigDye® (Life Technologies), and either the forward or reverse universal primer for each amplicon. Once complete, the sequencing reaction was precipitated using sodium acetate followed by a 70% ethanol wash (3 M NaOAc at 1/10th volume for a 300 mM final concentration and 2.5X volumes of EtOH). The DNA was dried down and then resuspended in EDTA and loaded on a 3730 DNA analyzer (Life Technologies). Bases were called from sequence trace files using phred and then assembled against a reference scaffold of the amplicon sequence using phrap (Ewing and Green, 1998; Ewing et al., 1998) . Sequence variants were identified by manual review of assemblies and sequence traces in Consed (Gordon et al., 1998) . We performed Sanger sequencing as described above on the original 22 tumor samples to validate Prlr variants that were called from WGS data and to extend the Prlr findings to 10 additional tumors and 35 non--tumor samples (Figure 1 and Figure S2 ). For two tumors in the original discovery set, additional FFPE samples were obtained, and sequenced on a MiSeq Illumina instrument using products of the same PCR protocol described above. Finally we sequenced an additional 9 FFPE samples by MiSeq, to evaluate the presence of Prlr mutations in DCIS tissues. Figure S1 . A clustal omega multiple protein sequence alignment is shown to visualize the effect of Prlr truncating mutations. Only residues 301 to 350 of the wild type PRLR are shown based on the reference sequence ENSMUST00000124470 (top row). All residues up to amino acid (aa) position 315 are preserved relative to the reference protein sequence. However, starting at position 316, mutated PRLR proteins are predicted to have either altered amino acid sequences and premature truncation, resulting in predicted protein sizes of 317 to 349 aa compared to the reference full--length sequence of 608 aa. Figure S5 . Truncated PRLR is endogenously expressed and co--expression with full--length PRLR leads to colony formation and tumor growth. Related to Figure 3 and Results.
Supplemental Figures

A) Endogenous expression of full--length (FL) and truncated (T) PRLR in Stat1--/--mammary cell lines detected by immunoprecipitation and Western blot analysis. B) Stat1--/--MEFs were transduced with vector alone (JAK2) or vector expressing full--length (FL/FL--JAK2), truncated (T/T--JAK2) or both full--length and truncated PRLR (FL/T--JAK2)
. Cell surface expression of PRLR was demonstrated by flow cytometry (blue) with secondary streptavidin--PE alone used as control (gray). C) 50,000 MEFs transduced as indicated were plated in soft agar in triplicate. Colonies were enumerated after 3 weeks. Plates were photographed without magnification and at 50X magnification (inset). D) Nude mice implanted with indicated MEFs or KRAS positive control were monitored for tumor growth. Animals were censored when progressively growing palpable tumors of at least 2 mm were detected. On Day 63, all remaining mice were sacrificed and evaluated for evidence of tumors prior to considering animals to be tumor--free. Co--expression of full--length and truncated PRLR in implanted MEFs resulted in significantly lower tumor--free survival than expression of full--length (log--rank test), truncated, vector alone or untransduced Stat1--/--MEFs. *p=0.0002, **p=0.0003, ***p<0.0001 Junction reads per million junction reads mapped (JPM) expression of the Full--Length (FL) and Truncated (T) isoforms of PRLR were calculated from raw counts and the ratio was defined as log2((FL + .01)/(T + .01)) (Boutin et al., 1989; Hu et al., 2001; Kline et al., 1999; Kline et al., 2002; Trott et al., 2003) . All isoforms could not be uniquely extracted and were simplified as defined below. Junction data was not available for junction 10B. JPM values for 3A and 10A were subtracted from the full--length JPM value to remove any contribution of the truncated isoforms to this calculation. The region of interest (ROI) corresponds to the "long" exon of PRLR and the upstream--most exon. Junction per Million (JPM) = (Raw Count of Junction)/(Sum of all hg19 Junctions) * 1,000,000 Full--length (FL) = (LF, IF) Truncated (T) = (S1a, S1b, Δ4 S1b, ΔS4--Δ7/11, Δ7/11, ΔS1) Region of Interest (ROI) = (chr5:35065191--35066204;hg19 and chr5:35068318--35068387;hg19) Supplemental Tables   Table S1 . SNV/Indel MAF file. Related to Table S6 . Details of all known isoforms of PRLR according to Ensembl, UCSC and UniProt. Related to Figure 4 and Results. Table S7 . Master sample sheet. Related to Figure 1 and Experimental Procedures. Table S8 . Summary of WGS data quality. Related to Figure 1 and Experimental Procedures. 
